South Korea has amended its pharmaceutical and biological product review systems to strengthen oversight of Vaccines, Blood Products, and Gene Therapy Products through updated approval regulations.
South Korea Tightens Rules on Vaccines, Blood, and Gene Therapeutics
Importers must meet stricter approval standards for a wider range of biological products.
What changed
Stricter review standards for inactivated and live vaccines.
Tighter documentation and safety assessments for blood products.
Gene therapy products are now formally included in the approval scope with specific evaluation criteria.
Who it affects
Vaccine importers must comply with enhanced review standards for all inactivated and live vaccines.
Blood product importers must provide stricter documentation and safety data for approval.
Gene therapy product developers must now follow specific evaluation criteria for market entry.
Regulation Analysis: South Korea’s Amendments to Pharmaceutical and Biological Product Review Systems
South Korea has strengthened oversight of vaccines, blood products, and gene therapy products through recent amendments to the Regulation for Pharmaceutical Approvals, Notifications and Reviews and the Regulations on Approval and Review of Biological Products. These changes introduce new submission standards, exemptions, and review criteria to enhance safety, efficacy, and regulatory efficiency. Below is a structured breakdown of the key amendments and their implications.
1. Key Amendments to the Regulation for Pharmaceutical Approvals, Notifications and Reviews
The following provisions were introduced or clarified in MFDS Notification No. 2023-4741:
| Regulation | Key Requirement | Deadline/Threshold | Authority |
|---|---|---|---|
| Synthetic Peptide Drugs | Clarifies approval review data requirements for synthetic peptide drugs referencing previously approved recombinant DNA (rDNA)-origin peptides. | Not specified | MFDS |
| Genotoxicity Test Exemption | Exempts submission of genotoxicity test data if no manufacturing process changes exist for drugs already used in Korea. | Not specified | MFDS |
| Non-Clinical Data | Accepts non-clinical data from alternative methods (e.g., non-animal tests) if validated during on-site inspections in OECD member countries. | Not specified | MFDS |
| SCI/SCIE Expansion | Expands acceptable scientific literature sources from Science Citation Index (SCI) to Science Citation Index Expanded (SCIE) for approval submissions. | Not specified | MFDS |
| Risk Management Plan (RMP) | Establishes submission standards for the Overview of Risk Management Plan (new Article 7-2 and Annex 6-3). | Not specified | MFDS |
| API Specifications | Expands recognition of multiple specifications for active pharmaceutical ingredients (APIs). | Not specified | MFDS |
| Pharmaceutical Descriptions | Standardizes the description method for pharmaceuticals (e.g., labeling, packaging). | Not specified | MFDS |
| MedDRA for Precautions | Requires MedDRA (Medical Dictionary for Regulatory Activities) to specify precautionary information. | Not specified | MFDS |
| Safety/Efficacy Reviews | Updates review standards for injections, ophthalmic solutions, and otic solutions. | Not specified | MFDS |
| Bioequivalence Tests | Allows replacement of bioequivalence tests with scientifically valid alternatives if bioequivalence testing is impossible or meaningless. | Not specified | MFDS |
| Oral Anticancer Drugs | Updates standards for conducting bioequivalence tests for oral anticancer drugs. | Not specified | MFDS |
| Stability Data Exemption | Exempts stability data submission for contract manufacturing if the entire process uses the same manufacturing method. | Not specified | MFDS |
| Preliminary Review | Clarifies documents required for preliminary review (new Article 55 and Annex 20). | Not specified | MFDS |
| Expedited Review | Adds National Essential Medicines (NEM) to expedited review categories. | Not specified | MFDS |
| Minor Changes | Expands the scope of minor changes that do not require approval (e.g., administrative updates). | Not specified | MFDS |
| CPP Exemption | Deletes the Certificate of Pharmaceutical Product (CPP) submission requirement for Common Technical Documents (CTD). | Not specified | MFDS |
| Enteric Nutritional Supplements | Permits the use of food raw materials in enteric nutritional supplements. | Not specified | MFDS |
2. Key Amendments to the Regulations on Approval and Review of Biological Products
The following provisions were introduced in MFDS Notification No. 2023-2932:
| Regulation | Key Requirement | Deadline/Threshold | Authority |
|---|---|---|---|
| Microbiome Drugs | Adds a new definition for drugs utilizing microbiome technology. | Not specified | MFDS |
| QbD System | Establishes quality review requirements for applications using the Quality by Design (QbD) system. | Not specified | MFDS |
| RMP for Self-Administered Injections | Mandates submission of a Risk Management Plan (RMP) for self-administered injections recognized by the Minister of MFDS. | Not specified | MFDS |
| RNA/DNA Vaccines | Introduces assessment criteria for RNA and DNA vaccines. | Not specified | MFDS |
3. Compliance Implications
For Vaccines, Blood Products, and Gene Therapy Products
- Enhanced Data Requirements:
- RNA/DNA vaccines now require specific assessment criteria.
- Synthetic peptide drugs referencing rDNA-origin peptides must comply with clarified data submission standards.
- Non-clinical data from OECD member countries may be accepted if validated during on-site inspections.
- Risk Management:
- RMP submission is now mandatory for self-administered injections and other high-risk biological products.
- MedDRA must be used for precautionary labeling.
- Exemptions and Flexibilities:
- Genotoxicity tests may be waived if no manufacturing changes occur.
- Stability data is exempt for contract manufacturing under identical conditions.
- Bioequivalence tests can be replaced with alternative methods if justified.
- Expedited Pathways:
- National Essential Medicines (NEM) qualify for expedited review.
- Minor changes (e.g., administrative updates) no longer require approval.
- International Alignment:
- SCIE is now accepted alongside SCI for literature submissions.
- QbD principles are formally integrated into quality reviews.
4. Timeline and Stakeholder Actions
- Comment Period: The public comment period for both notifications closed 60 days after issuance (e.g., 27 November 2023 for MFDS Notification No. 2023-474)1.
- Adoption/Enforcement: Dates for adoption and entry into force are to be determined1, 2.
- Stakeholder Steps:
- Review updated submission standards (e.g., RMP, QbD, MedDRA) for compliance.
- Assess eligibility for exemptions (e.g., genotoxicity tests, stability data).
- Prepare for expedited reviews if applying for NEM status.
- Monitor MFDS announcements for final adoption dates.
Summary Answer
South Korea’s recent amendments to the Regulation for Pharmaceutical Approvals, Notifications and Reviews1 and the Regulations on Approval and Review of Biological Products2 introduce stricter oversight for vaccines, blood products, and gene therapy products through:
- New data requirements (e.g., RNA/DNA vaccine criteria, synthetic peptide standards ).
- Mandatory Risk Management Plans (RMPs) for self-administered injections and other high-risk products.
- Exemptions for genotoxicity tests and stability data under specific conditions.
- Expanded flexibilities (e.g., non-animal test data, SCIE literature, QbD integration ).
- Expedited pathways for National Essential Medicines.
Stakeholders must align submissions with updated standards and monitor MFDS for final enforcement dates. All amendments aim to protect human health and safety2 while streamlining regulatory processes.
Sources
- ↩ Amendments to the “Regulation for Pharmaceutical Approvals, Notifications and Reviews” _notification https://docs.wto.org/imrd/directdoc.asp?DDFDocuments/T/G/TBTN23/KOR1172.DOCX
- ↩ Amendment to the Regulations on Approval and Review of Biological Products _notification https://docs.wto.org/imrd/directdoc.asp?DDFDocuments/T/G/TBTN23/KOR1150.DOCX